Biomedtracker

Report Library

Datamonitor NSCLC and Immunotherapy KOL Interview

February 29, 2016

Datamonitor interviewed an oncologist based in Seattle, WA to determine his current treatment practices and opinions on late-stage pipeline drugs for the treatment of NSCLC including immunotherapies.

If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).

Highlights

KOL thinks that the greatest unmet need is trying to figure out which patients are more or less likely to benefit from immunotherapy for lung cancer.
Opdivo will continue to have clear advantage in the market over Keytruda as molecular testing is a hurdle for drugs that are likely interchangeable (BMY, MRK).
He thinks combinations like Yervoy and Opdivo are provocative, but he is worried about toxicity and price (BMY).
KOL says “I have never seen a drug that adds so little cost so much” – in regards to Portrazza (LLY).
KOL believes Alecensa will be listed immediately for second –line and will be seen as a first line option after results from the ALEX trial (Roche).
He is plus/minus on Cyramza and thinks the pricing is aggressive given the benefit (LLY).

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.

Indications Covered:

Non-Small Cell Lung Cancer (NSCLC)

Additional Resources: